I was unable to attend the SGO Annual meeting this year due to a family commitment but I did follow along on X(Twitter).
To kept on top of the action, I followed SGO Social Media Ambassadors Social Media Ambassadors on X- @RiosDoriaMD , @nicoleflemingmd, @meddles28, and @ShannonWestin and others.
Here are some of their ovarian cancer research posts I found most interesting :
Dr Rubinstein presenting novel Trop-2 ADC at 3mg/kg dose led to 80% disease control rate in plat-resistant #ovariancancer. Most common toxicity stomatitis which can be managed with early intervention. #SGOMtg #SGO2025 pic.twitter.com/vBqb7Hus5n
— Nicole D. Fleming MD (@nicoleflemingmd) March 15, 2025
#SGOMtg- on the scene with Dr Fiona Simpkins to discuss impact of her work exploring WEE1 inhibition in CCNE1-expressing #ovariancancer #gyncsm #SGO2025 @nicoleflemingmd @RiosDoriaMD @meddles28 pic.twitter.com/jmNi8qk8Cv
— Shannon Westin, MD, MPH, FASCO (@ShannonWestin) March 15, 2025
Exciting data by Dr Simpkins from GOG 3066/DENALI study showing activity of Azenosertib in plat-resistant #ovariancancer stratified by cyclin E1 IHC overexpression. ORR 35% in cyclin E1 biomarker positive! #SGOMtg #SGO2025 pic.twitter.com/mlPRIc6AmM
— Nicole D. Fleming MD (@nicoleflemingmd) March 15, 2025
Dr. Herzog presenting @GOG PROFECTA-II/GOG-3044 trial of paclitaxel +/- afuresertib for platinum resistant ov cancer. Negative trial, but identified targets! @SGO_org @GOG #SGO2025 #SGOMtg pic.twitter.com/ZRz5NbAuPv
— erin medlin (@meddles28) March 15, 2025
Starting day 2 of scientific presentations @SGO_org! Dr Herzog presents data from GOG 3044 showing no benefit adding Afuresertib to weekly Taxol in plat-resistant recurrent #ovariancancer. #SGOMtg #SGO2025 pic.twitter.com/up5P6Zb0SZ
— Nicole D. Fleming MD (@nicoleflemingmd) March 15, 2025
EWOC-1 was a study of three different chemotherapy regimens . Use of carboplatin alone was associated with poorer survival.
Congratulations @JudeNawlo on evaluating post-EWOC practice patterns in elderly cohort #ovarinacancer pts! Pts w single agent carbo had worst outcomes- impt@to use platinum doublet when feasible. @SGO_org @GOG @IGCSociety @gyncsm pic.twitter.com/efZNiyyP29
— Bhavana Pothuri (@BPothuri) March 15, 2025
Mirv MIRASOL Study of ocular events.
During the #SGOMtg, Tashanna Myers, MD from Baystate Medical Center (@BaystateHealth) presents results from the phase 3 MIRASOL study, which tested the impact of treatment-emergent ocular events on health-related quality of life in patients with FRα-positive platinum-resistance… pic.twitter.com/UxE92NmdaD
— Moffitt Cancer Center (@MoffittNews) March 17, 2025
RAINFOL-01 study (NCT05579366)
Rinatabart sesutecan (Rina-S) a novel folate receptor alpha (FRα)–targeted antibody-drug conjugate (ADC). The treatment in heavily pretreated patients with platinum-resistant
ovarian cancer showed activity regardless of folate receptor alpha (FRα) expression
level.
Rina-S Generates Durable Responses in Advanced Platinum-Resistant Ovarian Cancer @EKLee_MD @DanaFarber @SGO_org #SGOMtg #SGO2025 #gyncsmhttps://t.co/4Fpsbj40Js
— OncLive.com (@OncLive) March 17, 2025
Low Grade Serous Ovarian Cancer
Combo of Avutometinib a Ras-Raf-MEK-ERK signaling inhibitor and Defactinib is small molecule inhibtor of focal adhesion kinase (FAK) for KRAS + recurrent low grade OC.
Avutometinib/Defactinib Combo Drives Responses in Recurrent Low-Grade Serous Ovarian Cancer @SGO_org #SGO2025 #SGOMtg #ovcahttps://t.co/LnYiBw2Vb4
— OncLive.com (@OncLive) March 17, 2025
Please let me know if I missed anything you felt was important for patients/ survivors.
I was happy to see ways that patient advocates, researchers and clinicians were able to #MultiplyYourImpact !
Thank you Dr Fader (@amandanfader) for your leadership! I look forward to your vision for the future, Dr Karen Lu (@karenluMD) !
Dee
Every Day is a Blessing!
